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Abstract
Introduction The role of routine lymphadenectomy for intrahepatic cholangiocarcinoma (ICC) is still controversial. The AJCC
eighth edition recommends a minimum of six harvested lymph nodes (HLNs) for adequate nodal staging. We sought to define
outcome and risk of death among patients who were staged with ≥6 HLNs versus <6 HLNs.
Materials and Methods Patients undergoing hepatectomy for ICC between 1990 and 2015 at 1 of the 14 major hepatobiliary
centers were identified.
Results Among 1154 patients undergoing hepatectomy for ICC, 515 (44.6%) had lymphadenectomy. On final pathology, 200
(17.3%) patients had metastatic lymph node (MLN), while 315 (27.3%) had negative lymph node (NLN). Among NLN patients,
HLN was associated with 5-year OS (p = 0.098). While HLN did not impact 5-year OS among MLN patients (p = 0.71), the
number of MLN was associated with 5-year OS (p = 0.02). Among the 317 (27.5%) patients staged according the AJCC eighth
edition staging system, N1 patients had a 3-fold increased risk of death compared with N0 patients (hazard ratio 3.03; p < 0.001).
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Conclusion Only one fourth of patients undergoing hepatectomy for ICC had adequate nodal staging according to the AJCC
eighth edition. While the six HLN cutoff value impacted prognosis of N0 patients, the number of MLN rather than HLN was
associated with long-term survival of N1 patients.
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Introduction
The American Joint Committee on Cancer (AJCC) staging
manual is the most common means to stratify cancer patients
with regard to prognosis. In the seventh edition AJCC staging
manual, a staging system for ICC was introduced for the first
time. The newly released eighth edition AJCC T categories
have several modifications for ICC staging, including the ad-
dition of tumor size to lesion number and vascular invasion
[1–7]. AJCC nodal (N) staging has also been a topic of ongoing
debate, as the role for routine lymphadenectomy for ICC has
been controversial with no standard approach to assessing
regional nodal information [2, 8, 9]. In one study using the
Surveillance, Epidemiology, and End Results (SEER) cancer
registry, Kim et al. reported on 749 patients who underwent
surgical resection of ICC between 1988 and 2011 [10]. In this
study, Kim et al. assessed the prognostic performance of
AJCC/UICC seventh N stage, lymph node ratio (LNR), and
log odds (LODDS) among patients with ICC [10].
Interestingly, after curative intent resection of ICC, LODDS
and LNRwere better predictors of long-term prognosis versus
seventh edition AJCC nodal staging. In particular, while LNR
performed well among patients who had >3 LNs harvested
and examined, LODDS was better at determining prognosis
among patients with ≤3 LN examined.
While nodal status appears to be an important factor in de-
termining prognosis of patients with ICC [11, 12], routine
lymphadenectomy is not always performed, especially in
Western centers [13, 14]. Data on pathological lymph node status
are, therefore, often lacking. Importantly, guidelines of the
European Association for the Study of the Liver (EASL) on
the management of ICC recommend the removal of lymph
nodes defined as suspicious according to preoperative imaging
[15]. However, the correlation of radiological lymph node status
assessment with pathological N status has yet to be determined.
As such, the objective of the current study was to correlate the
performance of radiological versus pathological assessment of
lymph node status among patients with resectable ICC.
Moreover, given that the newly released AJCC eighth edition
recommends the recovery of at least six lymph nodes for com-
plete pathologic staging, we sought to define the outcome of
patients who were Badequately^ (≥6 nodes harvested) versus
Binadequately^ staged (<6 nodes harvested) according to the
eighth edition of the AJCC staging manual [16].
Materials and Methods
Patient Demographic and Clinical Data
Patients undergoing liver surgery for histologically confirmed
ICC between 1990 and 2015 at one of the following 14 major
hepatobiliary centers were identified: Johns Hopkins Hospital,
Baltimore, MD; Stanford University, Stanford, CA;
University of Virginia, Charlottesville, VA; Emory
University, Atlanta, GA; Fundeni Clinical Institute of
Digestive Disease, Bucharest, Romania; Curry Cabral
Hospital, Lisbon, Portugal; Ospedale San Raffaele, Milan,
Italy; Royal Prince Alfred Hospital, University of Sydney,
Sydney, Australia; Eastern Hepatobiliary Surgery Hospital,
Shanghai, China; Beaujon Hospital, Clichy, France;
University of Ottawa, Ottawa, Ontario, Canada; Erasmus
University Medical Centre, Rotterdam, Netherlands;
Yokohama City University School of Medicine, Yokohama,
Japan; and University of Verona, School of Medicine, Verona,
Italy. The Institutional Review Board of each institution ap-
proved the study. Only patients who underwent curative intent
surgery were included, while patients with metastatic disease
and patients who underwent an R2 resection were excluded.
Standard patient demographic and clinicopathologic data
were collected including age, sex, American Society of
Anesthesiologists (ASA) physical status classification, and
presence of underlying liver disease, such as cirrhosis, chronic
hepatitis B infection, and chronic hepatitis C infection. Serum
level of carcinoembryonic antigen (CEA) and cancer antigen
(CA) 19-9 was also included. Data regarding treatment details
were collected including type of surgery and receipt of adju-
vant chemotherapy and radiotherapy. The type of surgery was
classified as wedge liver resection, minor resection (removal
of ≤2 Couinaud segment), and major resection (removal of ≥3
Couinaud segment) [17]. Resection margin status was record-
ed and classified as microscopically negative (R0) and micro-
scopically positive (R1). Tumor-specific characteristics in-
cluding tumor size, number, grade, number of lymph nodes
harvested, number of metastatic nodes, presence of vascular
invasion (macroscopic and microscopic), perineural invasion,
biliary invasion, and direct invasion of contiguous organs
were obtained. Lymphadenectomy was performed such that
the regional lymph nodes including the nodes in the
hepatoduodenal ligament (station 12), the nodes along the
common hepatic artery (station 8), and the nodes on the pos-
terior surface of the head of the pancreas (station 13) were
harvested, in addition, for left side ICC, also the nodes along
the trunk of left gastric artery (station 7). Data on tumor stage
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were also collected according to both the seventh and the
eighth edition AJCC staging system [1, 16]. Nodal status was
assessed preoperatively by endoscopic ultrasound echography
(EUS), computer tomography (CT) scan, magnetic resonance
imaging (MRI), and positron emission tomography (PET)
scan; nodes were classified on preoperative imaging as posi-
tive, negative, or suspicious. Date of last follow-up and vital
status were collected on all patients.
Statistical Analysis
Continuous variables were reported as medians with inter-
quartile ranges (IQRs), while categorical variables were re-
ported as whole numbers and percentages. The endpoint for
the survival analysis was overall survival (OS). OS was de-
fined as the time interval between the date of surgery and the
date of death. Time was censored at the date of the last follow-
up assessment for patients who were still alive at the time of
analysis. Survival curves were estimated using the Kaplan-
Meier method, and differences between the curves were com-
pared using the log-rank test. Univariate Cox proportional
hazard models were used to evaluate associations between
variables and OS. The coefficients from the Cox models were
reported as hazard ratios (HRs) with corresponding 95% con-
fidence intervals (CIs). A Bayesian model was developed to
analyze the prognosis of patients with or without metastatic
nodes (N1 versus N0) based on the number of harvested nodes
[18]. The results of the Bayesian model were presented as 5-
year OS and HR with associated 95% credible intervals (Cr
Is). All analyses were performed using the statistical software
programs STATA (v. 12.0, StataCorp, College Station, TX),
OpenBugs (v.2011), and R CRAN (v. 3.2.2, 2015) with the
packages Bsurvival,^ BHmisc,^ and BR2OpenBUGS.^ A
p value <0.10 was considered statistically significant.
Results
Baseline Characteristics of the Study Group
Among 1154 patients who underwent hepatectomy for ICC,
most patients were male (n = 638, 55.3%) and younger than
65 years (n = 712, 61.7%; Table 1). Based on the ASA phys-
ical status classification, 634 (54.9%) patients were ASA ≤2
and 520 (45.1%) patients were ASA 3 or 4. Preoperatively, a
minority of patients (n = 84, 7.3%) underwent neoadjuvant
chemotherapy. About two thirds of patients (n = 708,
61.4%) underwent a major hepatectomy, while 157 (13.6%)
underwent a wedge resection and 289 (25.0%) a minor hepa-
tectomy. A resection with negative margins (R0) was per-
formed in the majority of patients (n = 992, 87.2%), while
146 (12.8%) patients had R1 resections. Mass forming
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(n = 941, 87.0%) was the most common morphological sub-
type of ICC. Overall, 941 (81.5%) patients had a single tumor,
while 213 (18.5%) patients had multifocal disease. According
to the AJCC seventh edition T staging system, 487 (42.2%)
patients were classified as stage T1, 207 (17.9%) as stage T2a,
123 (10.7%) as stage T2b, 195 (19.9%) as stage T3, and 142
(12.3%) as stage T4. Using the AJCC eighth edition T staging
system, 249 (21.6%) patients were classified as stage T1a, 270
(23.4%) as T1b, 402 (34.8%) as T2, 167 (14.5%) as T3, and
66 (5.7%) as T4.
Radiological Nodal Status
A total of 785 (68.0%) patients had data on preoperative ra-
diological nodal staging. EUS, CT, MRI, and PET were used
to preoperatively assess nodal status in 19 (2.4% of 785), 383
(48.9% of 785), 307 (39.1% of 785), and 76 (9.7% of 785)
patients, respectively. Among radiological-staged patients,
nodal status was negative (R-NLN) in 608 (77.5% of 785)
patients, suspicious (R-SLN) in 118 (15.0% of 785), and met-
astatic (R-MLN) in 59 (7.5% of 785) patients. Patients with R-
NLN had a 5-year OS of 49.7% (IQR, 44.3–54.8) compared
with a 5-year OS of 30.1% (IQR, 18.7–42.4) for patients with
R-SLN and 25.8% (IQR, 12.5–41.4) for patients with R-MLN
(p < 0.001; Table 2, Fig. S1). Compared with patients with R-
NLN, patients with R-SLN (HR 1.55, 95% CI, 1.15–2.06;
p = 0.003) and R-MLN (HR 1.82, 95% CI, 1.27–2.62;
p = 0.001) were at higher risk of death (Table 2).
Among 317 (27.5%) patients who had data on both radio-
logical and pathological nodal evaluation, the incidence of
NLN was 66.5% (n = 127) among patients initially deemed
R-NLN compared with 42.5% (n = 34) among patients who
were preoperatively staged R-SLN; in contrast, the incidence of
NLN was only 34.8% (n = 16) among patients deemed preop-
eratively to be R-MLN. The incidence of MLN increased from
33.5% (n = 64) among patients who were R-NLN to 57.5%
(n = 46) and 65.2% (n = 30) among patients who were R-SLN
or R-MLN, respectively (p < 0.001; Table 3). Radiological
nodal status was associated with advanced disease (T3/T4
AJCC seventh ed. and eighth ed. stages; both p ≤ 0.003;
Table 3). Of note, the area under the receiver operating charac-
teristic (ROC) curve comparing nodes deemed preoperatively
as positive or suspicious versus documented metastatic nodal
disease on final pathology was 0.63.
Nodal Status
At the time of hepatectomy, nodes were harvested in 515
(44.6%) patients, while 639 (55.4%) patients did not undergo
lymphadenectomy. When lymphadenectomy was performed,
the median number of harvested lymph node (HLN) was 4
(IQR, 2–8). Overall, 200 (17.3%) patients had metastatic
lymph nodes (MLNs), and 315 (27.3%) patients had no evi-
dence of lymph node metastasis (NLN). Among the 200
(17.3%) patients with MLN, 110 (55.0% of MLN group) pa-
tients had 1 MLN, 65 (32.5% ofMLN group) 2–5 MLNs, and
25 (12.5% ofMLN group) ≥6MLNs. Among the 315 (27.3%)
patients with NLN, 67 (21.3% of NLN group) patients had 1
HLN, 131 (41.6% of NLN group) 2–5 HLNs, and 117 (37.1%
of NLN group) ≥6 HLNs. The 5-year OS of patients with
NLN was 44.4% (IQR, 36.9–51.6) versus 15.2% (IQR, 8.7–
23.4) for patients with MLN (HR 2.42, 95% CI 1.88–3.13;
p < 0.001; Fig. 1).
To verify the prognostic role of six HLNs as the minimum
number recommended by the AJCC eighth edition staging
system for an adequate nodal staging, MLN and NLN patients
were dichotomized in two groups with a cutoff of six HLNs.
Among the 200 (17.3%) patients with MLN, 100 (50.0% of
MLN group) patients had ≥6 HLNs with a 5-year OS of
17.9% (IQR, 8.6–29.9) versus a 5-year OS of 12.5% among
the 100 (50.0% of MLN group) patients who had <6 HLNs
(IQR, 4.7–24.2; p = 0.71; Fig. S2). Patients with MLN had a
similar risk of death when stratified by <6 versus ≥6 HLNs
(HR 1.07, 95% CI 0.75–1.52, p = 0.72). Among the 315
(27.3%) patients with NLN, 117 (37.1% of NLN group) pa-
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66.3) compared with a 5-year OS of 39.4% (IQR, 30.6–48.1;
p = 0.098; Fig. S3) among the 198 (62.9% of NLN group)
patients who had <6 HLNs. Interestingly, patients with NLN
who had <6 nodes harvested tended to have an increased risk
of death compared with patients who had ≥6 HLNs (HR 1.39,
95% CI 0.94–2.07, p = 0.098).
Patients Without Nodes Harvested
A total of 639 (55.4%) patients did not undergo lymphadenec-
tomy (Nx); Nx patients had a 5-year OS of 44.0% (IQR, 39.2–
48.7) (HR 1.18, 95% CI 0.96–1.47; p = 0.11) (Table 2). When
pathological Nx patients were stratified according to
Table 2 Comparison of nodal status—Kaplan-Meier analysis and risk of death
N = 1154 5-Year OS 95% CI p value HR 95% CI p value
Radiological nodal status <0.001
Negative 608 (52.7%) 49.7% 44.3–54.8 – – –
Suspicious 118 (10.2%) 30.1% 18.7–42.4 1.55 1.15–2.06 0.003
Positive 59 (5.1%) 25.8% 12.5–41.4 1.82 1.27–2.62 0.001
Not reported 369 (32.0%) 30.7% 25.3–36.2 1.57 1.30–1.90 <0.001
Pathological nodal status <0.001
Negative 315 (27.3%) 44.4% 36.9–51.6 – – –
Metastatic 200 (17.3%) 15.2% 8.7–23.4 2.42 1.88–3.13 <0.001
Not harvested 639 (55.4%) 44.0% 39.2–48.7 1.18 0.96–1.47 0.11
AJCC eighth edition N stage <0.001
N0 117 (10.1%) 54.9% 41.6–66.3 – – –
N1 200 (17.3%) 15.2% 8.7–23.4 3.03 2.08–4.42 <0.001
NX 837 (72.6%) 42.9% 38.6–47.1 1.46 1.04–2.07 0.031
Negative nodal status 0.098
NLN with ≥6 HLNs 117 (37.1%) 54.9% 41.6–66.3 - - -
NLN with <6 HLNs 198 (62.9%) 39.4% 30.6–48.1 1.39 0.94–2.07 0.098
Metastatic nodal status 0.72
MLN with ≥6 HLNs 100 (50.0%) 17.9% 8.6–29.9 – – –
MLN with <6 HLNs 100 (50.0%) 12.5% 4.7–24.2 1.07 0.75–1.52 0.72
Radiological nodal status in NHN <0.001
Negative 417 (65.3%) 52.3% 46.1–58.2 – – –
Suspicious 38 (5.9%) 24.8% 9.3–44.2 1.55 1.15–2.07 0.003
Positive 13 (2.0%) 20.1% 3.3–47.1 1.82 1.27–2.62 0.001
Not reported 171 (26.8%) 32.1% 24.3–40.0 1.58 1.31–1.90 <0.001
OS overall survival, CI confidence interval, HLN harvested lymph node, MLN metastatic lymph node
Table 3 Association between
radiological nodal status,
pathological nodal status, AJCC
seventh ed., and AJCC eighth ed.
T stages
Radiological modal status p value
Negative Suspicious Positive
Pathological nodal statusa <0.001
Negative 127 (66.5%) 34 (42.5%) 16 (34.8%)
Positive 64 (33.5%) 46 (57.5%) 30 (65.2%)
AJCC seventh edition T stagesb <0.001
T1/T2a/T2b 471 (77.5%) 74 (62.7%) 31 (52.5%)
T3/T4 137 (22.5%) 44 (37.3%) 28 (47.5%)
AJCC eighth edition T stagesb 0.003
T1a/T1b/T2 406 (66.8%) 70 (59.3%) 27 (45.8%)
T3/T4 202 (33.2%) 48 (40.7%) 32 (54.2%)
a n = 317 patients
b n = 785 patients
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preoperative radiological nodal status, 417 (65.3%) were in
the R-NLN group, 38 (5.9%) in the R-SLN, and 13 (2.0%)
in the R-MLN group; 171 (26.8%) did not have any informa-
tion on radiological node status (R-Nx). Among pathological
Nx patients, 5-year OS among patients with R-NLN was
52.3% (IQR, 46.1–58.2) versus 24.8% (IQR, 9.3–44.2) for
R-SLN, 20.1% (IQR, 3.3–47.1) for R-MLN and 32.1%
(IQR, 24.3–40.0) for R-Nx (Table 2). Compared with patients
who had R-NLN, patients with R-SLN (HR 1.55, 95% CI
1.15–2.07), R-MLN (HR 1.82, 95% CI 1.27–2.62), and R-
Nx (HR 1.58, 95% CI 1.31–1.90) had an increased hazard
of death (all p ≤ 0.003; Table 2).
AJCC Eighth Nodal Staging
Among the 317 (27.5%) patients with MLN or NLN with ≥6
HLNs—the cutoff recommended by the AJCC eighth edition
staging system—117 (36.9% of 317) patients were defined as
N0 and 200 (63.1% of 317) as N1. The 5-year OS of N0
patients was 54.9% (IQR, 41.6–66.3; Table 2) versus 15.2%
(IQR, 8.7–23.4) for N1 patients (p < 0.001; Fig. 2). In turn, N1
patients had an increased hazard of death compared with N0
patients (HR 3.03, 95% CI 2.08–4.42; p < 0.001).
To further investigate the effect of the number of HLN on
the prognosis of N0 and N1 patients, a Bayesian Weibull
model was developed. N1 patients had an increased risk of
death (HR 2.42, 95% Cr Int, 1.69–3.38) compared with N0
patients who had one HLN. Of note, when the number of
HLN was increased to 3, 6, 8, and 10, the risk of death among
N1 patients versus N0 patients increased incrementally to
2.61, 2.89, 3.11, and 3.34, respectively. Specifically, 5-year
OS among N0 patients increased with higher numbers of
HLN from 38.3% with 1 HLN to 42.7, 49.2, 53.4, and
57.3% with 3, 6, 8, and 10 HLNs, respectively. Conversely,
5-year OS among N1 patients did not varying considerably
when HLN increased, ranging from 9.7% with 1 HLN to only
15.5% with 10 HLNs (Table S1).
Discussion
Several studies have investigated a variety of clinicopatholog-
ical factors and long-term survival, identifying tumor size,
tumor number, vascular invasion, and lymph node metastasis
as independent predictors of OS and recurrence-free survival
(RFS) among patients undergoing surgery for ICC [2, 15, 19,
20]. In particular, the role of lymphadenectomy for ICC has
been extensively debated [2, 8–10]. In a recent meta-analysis
that evaluated the management of lymph node basin during
liver resection for ICC, the authors suggested that surgeons
should strongly consider lymph node dissection at the time of
surgery although there was insufficient data to support a
strong recommendation for routine lymphadenectomy [21].
The newly released eighth edition AJCC staging manual ad-
vocates, however, for recovery of at least six lymph nodes
during the time of surgery for ICC [16]. Given the large vari-
ability in lymphadenectomy among Eastern and Western cen-
ters, little data exist regarding the optimal number of lymph
nodes to harvest at the time of surgery for ICC. In addition, no
study has explicitly sought to evaluate the prognostic rele-
vance of preoperative radiological versus pathological lymph
node status. While several studies have evaluated the sensitiv-
ity, specificity, and predictive value of ultrasound, CT, MRI,
and PET [22–24], no study had assessed the prognostic ability
of preoperatively determine N status and long-term outcomes
following resection of ICC. The current study was important,
therefore, as we determined the prognostic impact of preoper-
ative radiologic nodal status. In addition, we assessed the
eighth AJCC edition’s recommendation for a minimum recov-
ery of six lymph nodes and its association with long-term
outcome among a large multiinstitutional cohort of patients
with ICC.
In addition to pathological staging, preoperative radiologi-
cal lymph node status, as assessed by EUS, CT, MRI, or PET,
was correlated with long-term prognosis among patients un-
dergoing resection of ICC (Table 2). Specifically, patients who
Fig. 1 Kaplan-Meier overall survival curves stratified by pathological
nodal status
Fig. 2 Kaplan-Meier overall survival curves stratified by AJCC eighth
edition nodal stages
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had metastatic lymph node disease on preoperative imaging
had a 5-year OS of only 25.8%, which was almost one half the
5-year OS (49.7%) among patients who had no lymph node
disease suspected on preoperative imaging. Interestingly, pa-
tients who had nodes deemed as suspicious on preoperative
imaging had a comparable 5-year outcome (30.1%) as patients
who had metastatic nodes. In fact, patients who had nodes
deemed as positive or suspicious on preoperative imaging
had an 82 and 55% increased hazard of death long-term com-
pared with patients who had no nodal disease.
Perhaps not surprisingly, pathological nodal status also was
associated with prognosis and, in fact, was much more strong-
ly correlated with long-term outcome than preoperative lymph
node assessment. Specifically, patients with pathologic N1
disease according to the AJCC eighth edition staging system
had almost a 2.5-fold increased risk of death at 5 years com-
pared with N0 patients. The superiority of pathological versus
radiological nodal status to predict long-term survival might
be expected. While preoperative imaging can often accurately
predict Btrue^ nodal status, some inaccuracy and lack of cor-
relation of preoperative imaging with final pathology can oc-
cur. Specifically, in the current study, the area under the ROC
curve comparing nodes that were Bpositive^ or Bsuspicious^
on preoperative imaging with true nodal disease on final pa-
thology was 0.63. These data suggest that the correlation of
preoperative imaging to detect nodal disease was good to fair.
Moreover, radiological node status was also correlated with
both AJCC seventh and eighth editions’ T stages, as patients
with advanced T stage disease were more likely to have pos-
itive or suspicious nodes on the preoperative imaging
(Table 3).
Recently, the AJCC eighth edition proposed a cutoff of six
lymph nodes to N stage patients adequately. The impact of
number of nodes examined has not been examined among
patients undergoing resection of ICC. As such, we investigat-
ed the effect of a cutoff of six nodes on long-term outcome. Of
note, OS among patients with N0 disease who had ≥6 HLNs
was 54.9%, which was markedly better than the 15.2% sur-
vival noted among patient with N1 disease. Perhaps of more
interest, when assessed using a Bayesian Weibull model, the
5-year OS of N0 patients improved with increasing numbers
of HLN, while the 5-year OS of N1 patients did not change
with a higher number of HLN (Table S1). In addition, while
the 5-year OS of patients with N1 disease who had ≥6 HLNs
was no different than patients who had <6 HLNs, the 5-year
OS of patients with N0 disease with <6 HLNs was somewhat
worse versus N0 patients who had a more thorough lymph
node harvest of ≥6 nodes.
The study had several limitations that should be considered
when interpreting the results. While one strength of the current
report was that it involved multiple centers, the multiinstitutional
nature likely led to different radiological imaging techniques. In
turn, the sensitivity and specificity of these different techniques
in staging the nodal basin may vary [23–25]. The multicenter
nature of the study also did not allow for standardization of
operative or perioperative approach, especially in terms of per-
formance and extent of lymphadenectomy. Finally, the long du-
ration and the multiinstitutional nature of the study likely caused
some heterogeneity in ICC treatment approach. However, given
the rarity of ICC, obtaining data from multiple centers increased
the sample size and made the data more generalizable.
Conclusion
In conclusion, while pathological nodal status was strongly
associated with long-term outcome, only one fourth of pa-
tients undergoing liver resection for ICC had adequate nodal
staging according to the newly released AJCC eighth edition
staging system. Moreover, our results suggested that radiolog-
ical lymph node staging could be inaccurate in up to 40% of
patients and should not be considered a valid alternative to
lymphadenectomy. Furthermore, the best ability to discrimi-
nate between patients with favorable prognosis and patients
with poor prognosis based on the lymph node status was
reached when ≥6 lymph nodes were harvested. In other words,
the quality of the lymph node staging in terms of hazard of
death of metastatic patients compared with non-metastatic pa-
tients increased from 1.6 to 1.8 with radiological assessment
to 2.4 with pathology assessment; of note, the hazard of death
increases to 3-fold when the AJCC eighth ed. staging system
recommendations were fulfilled. While the six HLN cutoff
value was associated with prognosis among patients staged
as N0, the number of HLN was not associated with long-
term survival among patients with N1 disease. These data
serve to emphasize the important prognostic role of patholog-
ical staging of nodal disease among patients undergoing re-
section of ICC.
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